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Introduction: The Dutch Gynecological Oncology Audit (DGOA) was initiated in 2014 to serve as a
nationwide audit, which registers the four most prevalent gynecological malignancies. This study pre-
sents the first results of clinical auditing for ovarian cancer in the Netherlands.
Methods: The Dutch Gynecological Oncology Audit is facilitated by the Dutch Institute of Clinical
Auditing (DICA) and run by a scientific committee. Items are collected through a web-based registration
based on a set of predefined quality indicators. Results of quality indicators are shown, and benchmarked
information is given back to the user. Data verification was done in 2016.
Results: Between January 01, 2014 and December 31, 2018, 6535 patients with ovarian cancer were
registered. The case ascertainment was 98.3% in 2016. The number of patients with ovarian cancer who
start therapy within 28 days decreased over time from 68.7% in 2014 to 62.7% in 2018 (p < 0.001). The
percentage of patients with primary cytoreductive surgery decreased over time (57.8%e39.7%, P< 0.001).
However, patients with complete primary cytoreductive surgery improved over time (53.5%e69.1%,
P < 0.001). Other quality indicators did not significantly change over time.
Conclusion: The Dutch Gynecological Oncology Audit provides valuable data on the quality of care on
patients with ovarian cancer in the Netherlands. Data show variation between hospitals with regard to
pre-determined quality indicators. Results of ‘best practices’ will be shared with all participants of the
clinical audit with the aim of improving quality of care nationwide.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
In the last decades, clinical audit registries have been introduced
for various conditions in European countries containing
population-based data [1e3]. For gynecological malignancies, au-
dits have also been established. A European example is the Swedish
Quality Registry for Gynecologic Cancer; this population-based
registry covers about 95% of all gynecological malignant tumorsal Center, Geert Grooteplein
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ecological Oncology Audit (Dand was initiated in 2010. This registry includes patients with
ovarian, cervical, endometrial, and vulvar cancer [4]. Such registries
use a set of quality indicators concerning quality aspects of the
diagnosis and treatment of patients with gynecologic cancers.
Clinical registries have been acknowledged as an essential tool for
quality assessment and provide feedback to participating hospitals,
leading to improved patient outcomes [5].
In recent decades, various steps were taken in the Netherlands
to improve the quality of care. Centralization of care was imple-
mented since themid-1980s for cervical and vulvar cancer [6,7]. For
advanced ovarian cancer, centralization was initiated in 2010,
following the requirements set by the national health authorities
[8]. Centralization of ovarian cancer treatment came with qualityunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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allowed to perform cytoreductive surgery within hospitals with a
minimum of 20 cytoreductive surgery procedures annually [8].
Centralization aimed to improve the result of the cytoreductive
surgery since survival has a direct relation to the completeness of
the cytoreductive surgery [9]. Following the centralization of sur-
gical care in the Netherlands, the number of hospitals performing
cytoreductive surgery for advanced ovarian carcinoma reduced
from nearly 90 before 2010 to 23 in 2019 [10]. Another restriction
by the health authorities involved the staging procedures for low
stage ovarian carcinoma, which was only allowed in those hospitals
performing at least 20 cytoreductive surgery per year [11].
The surgical care for patients with a gynecological malignancy is
currently organized within eight regional cancer networks.
Although the number of hospitals performing cytoreductive sur-
gery decreased, variation between these regional cancer networks
concerning effectiveness may still exist. To evaluate differences in
quality of care between providers, a nationwide gynecological-
oncology audit was initiated to gain more insight into patient
outcomes in daily practice [3].
At the end of 2013, following an increased demand for insight in
the variation of care and its influence on the quality of care deliv-
ered to patients with cancer in the Netherlands, the Dutch Gyne-
cological Oncology Audit (DGO) was initiated by the Dutch
Gynecological Oncology Working Group (WOG) and facilitated by
the Dutch Institute of Clinical Auditing (DICA) [5]. The registry's
primary goal is to evaluate the results of treatment given to patients
with a gynecological malignancy and identify factors that could
improve the outcomes in these patients. This article illustrates the
key elements and processes of the Dutch Gynecological Oncology




The Dutch Institute of Clinical Auditing (DICA) was founded in
2010 and since then they facilitated several medical societies in The
Netherlands to initiate population-based audits, using the colo-
rectal audit as a blueprint [12]. The key element to their clinical
auditing model is that healthcare professionals themselves deter-
mine the audit objectives and decide which aspects of care should
be registered to gain insight into the outcomes of patients [13].
The Dutch Gynecological Oncology Audit scientific committee
consists of four gynecologic oncologists, two radiation oncologists,
one representative of the Netherlands Comprehensive Cancer Or-
ganization, the Netherlands (NCCN), and two members from the
gynecological oncology patient advocate organization "Stichting
Olijf". The scientific committee meets four times a year and de-
termines the audit objectives and the dataset's content for each
tumor type.
Dataset of the Dutch Gynecological Oncology Audit
The Dutch Gynecological Oncology Audit has been a mandatory
registry since January 2014 and contains detailed clinical data of all
patients treated with any form of therapy for ovarian-, cervical-,
endometrial- or vulvar cancer in the Netherlands. Since 2018 a
registration for patients treated with radiotherapy was added
(DGOA - Radiotherapy). The registered items are divided into the
following categories: patient identification, tumor characteristics,
surgical and pathology items, radiotherapy and chemotherapy
items. Follow up data are registered for five years after primary
treatment. Approval of an Institutional Review Board was not2
needed since all data are anonymized and processed by a third
party.Data collection and analysis of the data
Data are either prospectively collected via a web-based survey
from themedical record by gynecological oncologist or delivered by
trained data managers from of the Netherlands Comprehensive
Cancer Organization; the division in supply is almost equally
divided. All data delivered are checked by the treating physician
before it is sent to a third party, Medical Research Data Manage-
ment (MRDM), who anonymizes the data. All patients seen by the
gynecologic oncologist are captured in the data. The anonymized
data are sent to DICA, where analysis of the data takes place. The
data science team of the Dutch Institute of Clinical Auditing pro-
vides results of benchmarked quality indicator to the participating
hospitals through a secured web-based dashboard. Hypothetically,
it might be that patients were registeredmore than once, especially
when treatment was performed in more than one hospital (i.e.,
surgery in a center hospital and chemotherapy in a non-center
hospital). In order to prevent this, the registry website specifies
specific rules which hospital should register a patient. Registration
is usually performed by the gynecological oncology center, where
the most extensive surgery was performed, e.g. such as staging or
cytoreduction for ovarian cancer [14].Data verification in the Dutch Gynecological Oncology Audit
The data entered in the Dutch Gynecological Oncology Audit
was verified in 2016. This data verification process aimed to
determine if all patients meeting the inclusion criteria were
correctly registered in the registry and if data were accurate. The
scientific committee of the Dutch Gynecological Oncology Audit
selected the items to verify. All participating hospitals received an
invitation to participate in this voluntary verification process, after
which hospitals were randomly selected. Data verification was
performed by trained data managers and verified by a third party
consisting of representatives of the scientific committee of the
Dutch Gynecological Oncology Audit, the Dutch health and youth
care inspectorate, the patient federation, and a statistician. Data in
the Electronic Health Records of the selected hospitals were
compared with the registered data in Dutch Gynecological
Oncology Audit. The accuracy of the data was measured through
any discrepancies found against the total number of patients
checked [15].Quality indicators
In 2014 the quality indicator set of the Dutch Gynecological
Oncology Audit consisted of four structure indicators and five
process indicators (Appendix A1 & A2) [16]. This was evaluated
over the years, and in 2018 the set included one structure indicator,
two process indicators, and four outcome indicators. At the start of
the registry the main focus was on developing quality indicators for
ovarian cancer with a future perspective to develop quality in-
dicators for the other malignancies. This resulted in a quality in-
dicator set mainly focusing on ovarian cancer. The scientific
committee evaluates this quality indicator set each year. New
quality indicators are developed in collaboration with representa-
tives of the Dutch Society of Obstetrics and Gynecology, the
Federation of Medical Specialties, the Dutch Health and Youth Care
Inspectorate, health insurance companies and patient
organizations.
Table 1
Patient and tumor characteristics of patients with ovarian cancer registered in the
Dutch Gynecological Oncology Audit between 2014 and 2018.
Number of patients 6535
Age, years



























Histology type as registered per tumor
Epithelial 5826 (89.2)
Non epithelial 324 (5.0)
Other: 123 (1.9)
Missing 262 (4.0)
a ASA score: American Society of Anesthesiologists scoring system.
b BMI: Body Mass Index.
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A goal of the Dutch Gynecological Oncology Audit at its initia-
tion in 2014 was to improve the quality of care by public trans-
parency of reliable hospital-specific outcome information. Quality
indicators are used to achieve this goal by making the results
transparent to the specialists through benchmarked data in funnel
plots. The results of publicly available quality indicators are dis-
cussed in annual meetings where all parties involved in national
healthcare participate [2].
Analyses of the Dutch Gynecological Oncology Audit data
Patient, tumor, and treatment characteristics are reported for
ovarian cancer from January 2014 to December 2018 collectively.
The results of the process and outcome indicators are compared
over the years using the chi-square test. Hospital variation is shown
for a process and an outcome indicator using funnel plots. R sta-
tistical package version 1.2.5019 (R Foundation for Statistical
Computing, Vienna, Austria) was used to analyze the data.
Results
Between January 01, 2014 and December 31, 2018, a total of 6535
patients with ovarian cancer were registered in the Dutch Gyne-
cological Oncology Audit. Patient, tumor, and treatment charac-
teristics are depicted in Table 1. Over the years, the registry became
more mature, which resulted in a higher number of registered
patients in more recent years than at the start of the registry
(Appendix:A3).
Data verification results
According to the data verification in 2016 completeness of data
included in the registry was 98.3%. Accuracy on selected items was
checked, and most items had an accuracy ranging from 95 to 98%.
However, 'FIGO classification' and 'date of discharge' had an accu-
racy of 87.8% and 27%, respectively (Appendix: A4).
To check if there were no double entries, an analysis of valid
social security numbers was done by Medical Research Data Man-
agement in 2019. The analysis was performed on the entire DGOA
database (September 2019). At that moment, the Dutch Gyneco-
logical Oncology Audit included 22.801 treatment records for all
tumors (treatment records do not correspond to unique patients as
patients could receive multiple treatments). The analysis was only
possible on data supplied through direct entry by the gynecologist,
which was 46.9% (10689 records) and 97.9% of these records were
found to have unique social security numbers. This analysis showed
that double registration in the database is not a frequently occur-
ring problem and reinforces the data's quality. The data supplied by
the Netherlands Comprehensive Cancer Organization by batch
(52.1% of the data) is prevented from doubling since they create a
separate unique patient number.
Quality indicator set and outcome
Table 2 shows the results over time for the various indicators
including the specific inclusion criteria for each indicator. Per-
centages are national averages calculated over the group of patients
included in the nominator of the indicator. The Quality indicator set
and is shown in Appendix A1. The indicator 'Percentage of patients
with ovarian cancer with less than 28 dayswaiting time before start
treatment’ significantly decreased over time (2014: 68.7% - 2018:
62.7% P< 0.001), meaning thatmore patients waited longer than 28
days to get any form of initial treatment. In addition, the indicator3
regarding 'The percentage of patients who underwent primary
cytoreductive surgery' decreased over time as well (57.8% % - 39.7%,
P< 0.001), though patients with a complete primary cytoreductive
surgery’ improved over time (53.5%e69.1%, P < 0.001). Complete
staging and mortality fluctuated over the years, but changes were
not statistically significant.Quality indicator results on hospital level
Fig. 1 shows the funnel plot for waiting time (<28 days) between
the first visit at the hospital of treatment and the start of treatment
collectively for the years 2014e2018. Positive as well as negative
outliers were identified: three hospitals had a significantly shorter
waiting time before the start of treatment, and four hospitals had
significantly longer waiting times.
Fig. 2 shows hospital variation in the percentage of patients with
complete primary cytoreductive surgery between 2014 and 2018.
For hospitals treating more than 50 patients during the study
period, the percentage of a complete primary cytoreductive surgery
(defined as no residual disease) varied between 39% and 84%, with
three hospitals having significantly less favorable results on this
outcome indicator than the national average.Discussion
The Dutch gynecological clinical audit was created in order to
register data from gynecologic malignancies (ovarian, vulvar, cer-
vical and endometrial cancers) and to measure outcomes. Up till
now, the analysis of quality of care has been analyzed over a period
Table 2
Results for ovarian quality indicators in the Dutch Gynecological Oncology Audit.
Indicator Inclusion 2014 2015 2016 2017 2018 p
1.Number of surgical patients registered for ovarian
cancer. (structure)
Surgery with the intent of staging or cytoreductive surgery. 1072 1290 1352 1410 1411
2. Percentage of patients with ovarian cancer with 28
days waiting time till the start of the treatment
process. (process)
Time fromwhen the patient is first seen by a gynecologist-oncologist to the
start of a treatment procedure
68.7 65.9 64.0 63.2 62.7 <0.001
3. Percentage of patients with low stage ovarian cancer
where surgical staging is complete at the primary
surgery. (outcome)
FIGO I - IIA
Complete staging procedure; sampling of ascites fluid, removal of adnexa
and uterus, infracolic omentectomy, 5 biopsies of the peritoneum, both
pelvic and para-aortic lymph node sampling required, 10 lymph nodes.
17.2 8.3 19.4 21.9 22.5 0.226
4a Percentage of patients with advanced ovarian cancer
with primary cytoreductive surgery. (outcome)
(FIGO IIBeIV) 57.8 48.3 41.2 46.8 39.7 <0.001
4b. Percentage of patients with advanced ovarian
cancer with complete primary cytoreductive surgery.
(outcome)
FIGO IIBeIV 53.5 68.6 72.5 66.7 69.1 <0.001
4c. Percentage of patients with advanced ovarian cancer
with complete interval cyto-reductive surgery.
(outcome)
FIGO IIBeIV 54.1 57.8 59 62.5 66.2 0.134
5. Percentage of patients with ovarian cancer and a
surgical complicated course within 30 days after the
procedure. (outcome)
7.0 6.9 8.7 9.4 7.7 0.149
6. Percentage of patients with ovarian cancer
undergoing surgery with 30-day mortality.
(outcome)
0.4 0.7 0.4 0.9 0.4 0.614
Fig. 1. Indicator 2: Percentage of patients registered in the DGOA with less than 28 waiting time to start any therapy for ovarian cancer between 2014 and 2018 for each individual
hospital.
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audit was not only to establish the status of care provided but also
to identify elements of the clinical care process amenable for
improvement. At the end of 2018 a total of 6535 patients with a
gynecological malignancy were registered in the Dutch Gyneco-
logical Oncology Audit, and case ascertainment reached almost
100% for most items. Outcome of quality indicators for ovarian
cancer fluctuated over the years and showed variation between
regions, indicating that there is room for overall improvements.
In the United States, tumor-specific quality indicators are
formulated by the SGO [17,18]. In 2015, Liang et al. published results
on compliance on ovarian cancer quality indicators by the SGO in a
cohort of 123 patients. In the ovarian cancer quality indicator set,
the indicator ‘complete staging of patients with early-stage ovarian
cancer’ appears most similar to ours [19]. Unfortunately, a4
comparison between results is not possible since the indicator is
slightly different from ours as the SGO only included patients with
FIGO I-IIIB [18], whereas the Dutch Gynecological Oncology Audit
included all stages. To our knowledge, there are no population-
based results of similar quality indicators for gynecological
oncology yet which makes international comparison not possible
yet.
The first analysis of the ovarian quality indicators of the Dutch
Gynecological Oncology Audit shows that they vary over time and
there are differences between hospitals. The indicator “Waiting
time between diagnosis and start treatment” shows that over time
patients waited longer to start with treatment after being diag-
nosed with ovarian cancer. A previous report comprising one re-
gion in The Netherlands showed conflicting results; in this
particular region, the waiting time improved after the
Fig. 2. Indicator 4b: Number of patients in each individual hospital who underwent complete primary cytoreductive surgery and were registered in the DGOA between 2014 and
2018.
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was only single-centered, it was also performed shortly after
centralization. Since the prolonged waiting time could be influ-
enced by the nature of the initial therapy (surgery or chemo-
therapy), a sub-analysis was performed on patients starting with
neoadjuvant chemotherapy. This analysis showed an increase in
waiting time; from 34% of patients starting with neoadjuvant
chemotherapy within 28 days in 2015 to 16% in 2018. This finding
did not meet our expectations, and one hypothesis could be that
centralization entailed organizational problems, which, for
example, resulted in longer waiting times. Another explanation
could be that diagnostic procedures are more often undertaken to
ensure the diagnosis ovarian carcinoma before start treatment. For
this reason, we added items in the survey since 2020 to provide
details on the diagnostic process.
The indicator “percentage of complete primary cytoreductive
surgery” shows a significant increase over the years. Although not
statistically significant, the percentage complete interval cytore-
ductive surgery also increased over time. This trend can be
explained by centralization. By establishing volume standards in
2010, hospitals were required to annually perform a minimum of
20 cytoreductive surgery. A stricter selection of patients for primary
cytoreduction, as reflected by an increase in the number of patients
treated with interval cytoreductive surgery, may also have influ-
enced these results.
To fulfil the purpose of the registry, its scientific committee will
focus on the reduction of hospital variation, through the identifi-
cation of best practices and revealing the mechanisms responsible
for the better outcomes (Figs. 1 and 2). In addition, data quality
should be maintained by registration directly from the electronic
patient records, which also reduces the registry burden for medical
specialists. Furthermore, next to a core dataset per tumor type, the
focus of the registry should be dynamic and guided by de-
velopments in international literature and incorporate these in
quality indicators, which are case-mix corrected. Lastly, if similar
indicators are used internationally, collaboration with other coun-
tries will enable us to compare outcomes between countries and
might identify best practices and improve the quality of care on a
much broader scale. The ESGO quality indicators for cytoreductive5
surgery for ovarian carcinoma are a good example of an interna-
tionally accepted set of quality indicators making comparisons
between countries possible [21].
The strengths of this study include the population-based nature
without exclusion of any subgroups. Therefore, it gives insight in
the results of the "real world". With this "real world" data, clinical
auditing aims to improve the standard of care through identifying
hospitals that are outliers to both sides. From this feedback, infor-
mation improvement programs can be initiated to clarify under-
lying mechanisms [12]. An additional strength is the use of data
verification reports to test the accuracy and completeness of its
data, making it more reliable. One of the examples is the visible low
percentage of 'date of discharge’ at the start of the registry.
Following the data verification, this variable became mandatory
since it was used to calculate indicator 5 “Complicated course”. This
resulted in an almost complete entry of date of discharge of 98% in
the years after (data not shown).
Nevertheless, the audit has its limitations. Although population-
based, some patients with gynecological malignancies were not
registered because these patients were not seen by a gyne-
oncologist but by the medical oncologist only who do not provide
information in the survey. The Netherlands Comprehensive Cancer
Organization registers all patients with malignancies of whom a
pathological diagnosis is available. With their data, it is possible to
get a more complete overview and identify how many of these
patients were not registered. (Appendix: A2). The differences in
numbers are minimal for ovarian cancer.
In conclusion, the initiation of the Dutch Gynecological
Oncology Audit registry came with hurdles and still allows for
further improvement. Although, recurring issues regarding regis-
tration burden, these results give an insight into ovarian cancer
outcomes in the Netherlands with future perspectives for the other
malignancies as well. Presenting benchmarked data to the indi-
vidual hospitals will result in a discussion on how to decrease
hospital variation and evaluate the quality of care with the aim to
improve outcomes for patients with ovarian cancer. This process
will be used in the future as a template to gain insight and improve
quality of care for patients with cervix, vulva or endometrial cancer.
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1 Number of surgical patients registered for one of the
gynecological tumors
structure OVEC* O: Surgery with the intent of staging or cytoreductive surgery.
2 Percentage of patients with ovarian cancer with28 days waiting
time2 until the start of the treatment process.
process O Time from when the patient is first seen by a gynecologist-oncologist to the start
of a treatment procedure
3 Percentage of patients with low stage ovarian cancer (FIGO Ie IIA)
where surgical staging is complete at the primary surgery.
outcome O A complete staging procedure involves sampling of ascites fluid, removal of
adnexa and uterus, infracolic omentectomy, at least 5 biopsies of the peritoneum,
minimal of 10 lymph nodes of at least 5 different locations (required: para aortal
and para caval)
4 Percentage of patients with advanced ovarian (FIGO IIBeIV)
cancer where complete cytoreductive surgery is achieved.
outcome O cytoreductive surgery can include a primary or interval procedure. A complete
was considered when there is no macroscopic tumor in the abdomen.
5 Percentage of patients with a surgical complicated course within
30 days after the procedure.
outcome O A composite measure of: Clavien Dindo grade 3 or higher with a prolonged
hospital stay of more than 14 days.
6 Percentage of patients with undergoing surgery with 30-day
mortality.
outcome O
7 Percentage of patients who receive treatment with curative
intention for ovarian cancer that are alive after 5 years
outcome O
8 Percentage of patients who participated to the Patient Reported
Outcome Measures (PROMs) survey.
process OVEC*
A2





1 Are all patients eligible for exclusion in the Dutch Gynecological Oncology Audit registered? structure Ovarian
2 Volume of cytoreductive surgery for ovarian cancer. Structure Ovarian
3 Amount of working gynecological oncologist and amount of working gynecologist with oncologic interest per hospital. Structure Ovarian
4 Standard of psychological care for patients with a gynecologic tumor. Structure Ovarian
5 Percentage of patients, receiving therapy for ovarian cancer of whom the information in the Dutch Gynecological Oncology Audit is
complete.
Process Ovarian
6 Percentage of patients with surgical staging or cytoreductive surgery done by a gynecologic oncologist. Process Ovarian
7 Percentage of patients discussed in a multidisciplinary team meeting (MDT). Process Ovarian
8 Percentage of patients with surgical treatment for ovarian cancer who have a complete pathology report. Process Ovarian
*O ¼ Ovarian, V¼ Vulvar, E ¼ Endometrial, C¼ Cervical.
A3
Number of patients registered in the National Comprehensive Cancer Organization,
the Netherlands (NCCN) and the Dutch Gynecological Oncology Audit (DGOA)




2017 1359 1410CRediT authorship contribution statement
N.M.S Baldewpersad Tewarie: Writing - original draft, Formal
analysis, Project administration, Visualization. W.J. van Driel:
Writing - original draft, Conceptualization, Writing - review &
editing, Supervision. M. van Ham: Writing - review & editing, Su-
pervision. M.W. Wouters: Conceptualization, Writing - review &
editing, Supervision. R. Kruitwagen: Conceptualization, Writing -
review & editing, Supervision.6
Declaration of competing interest




* Reasons of wrongly registered data: not registered while variable should be
registered, registered while variable should not be registered, wrong variable
registered.
A4
Results of external data verification Dutch Gynecological Oncology Audit 2016 [15].
Completeness of Data
Registered Incorrectly registered/missing Completeness
Sample size: 351 n n %
Included in DGOA 345 6 98.3
Accuracy of data
Variables: correctly registered wrongly registered* completeness
Sample size:345 n n %
Vital status 344 1 99.7
Date of death 345 0 100
Patient discussed in multidisciplinary team 337 8 97.7
Histological type of tumor 343 2 99.4
Differentiation grade of tumor 325 20 94.2
FIGO classification 303 42 87.8
Date of surgery 341 4 98.8
Treatment by gynecologist oncologist 340 5 98.5
Type of surgical procedure 342 3 99.1
Complications within 30 days 311 34 91.1
Type of re intervention 341 4 98.8
Re intervention with general anesthesiology 341 4 98.8
Date of discharge 93 252 27
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